U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Bladder Carcinoma

MedGen UID:
1664919
•Concept ID:
C4725675
•
Neoplastic Process

Definition

Bladder carcinoma that does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, Cheville J, Lucien F
Oncologist 2023 Apr 6;28(4):297-308. doi: 10.1093/oncolo/oyac263. PMID: 36745503Free PMC Article
Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
Yang HY, Wu CY, Chen JJ, Lee TH
Int J Mol Sci 2020 Nov 26;21(23) doi: 10.3390/ijms21238993. PMID: 33256165Free PMC Article
Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K, Bellmunt J
Expert Rev Clin Pharmacol 2020 Jan;13(1):1-6. Epub 2019 Dec 22 doi: 10.1080/17512433.2020.1702025. PMID: 31810398

Recent clinical studies

Etiology

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS
Cancer 2022 Mar 15;128(6):1194-1205. Epub 2021 Dec 9 doi: 10.1002/cncr.34057. PMID: 34882781
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.
Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM
Lancet 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6. PMID: 29976469
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA
J Clin Oncol 2016 Jun 1;34(16):1935-44. Epub 2016 Jan 25 doi: 10.1200/JCO.2015.64.4070. PMID: 26811532Free PMC Article

Diagnosis

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Urothelial carcinoma in the era of immune checkpoint inhibitors.
Khalife N, Chahine C, Kordahi M, Felefly T, Kourie HR, Saleh K
Immunotherapy 2021 Aug;13(11):953-964. Epub 2021 Jun 29 doi: 10.2217/imt-2021-0042. PMID: 34184561
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
Clin Cancer Res 2021 Sep 15;27(18):5123-5130. Epub 2021 Jun 9 doi: 10.1158/1078-0432.CCR-20-4175. PMID: 34108177Free PMC Article
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J
Clin Cancer Res 2021 Jan 1;27(1):43-51. Epub 2020 Oct 27 doi: 10.1158/1078-0432.CCR-20-2488. PMID: 33109737
Localized bladder cancer.
Izawa JI, Grossman HB
Curr Treat Options Oncol 2000 Dec;1(5):423-32. doi: 10.1007/s11864-000-0070-5. PMID: 12057150

Therapy

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
Clin Cancer Res 2021 Sep 15;27(18):5123-5130. Epub 2021 Jun 9 doi: 10.1158/1078-0432.CCR-20-4175. PMID: 34108177Free PMC Article
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA
J Clin Oncol 2016 Jun 1;34(16):1935-44. Epub 2016 Jan 25 doi: 10.1200/JCO.2015.64.4070. PMID: 26811532Free PMC Article

Prognosis

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
Antibody-Drug Conjugates in Uro-Oncology.
Sigorski D, Różanowski P, Iżycka-Świeszewska E, Wiktorska K
Target Oncol 2022 May;17(3):203-221. Epub 2022 May 14 doi: 10.1007/s11523-022-00872-3. PMID: 35567672
Immunotherapy Advances in Urothelial Carcinoma.
Jain RK, Snyders T, Nandagopal L, Garje R, Zakharia Y, Gupta S
Curr Treat Options Oncol 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x. PMID: 30554335
Prospects and progress of immunotherapy for bladder cancer.
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM
Expert Opin Biol Ther 2017 Nov;17(11):1417-1431. Epub 2017 Aug 23 doi: 10.1080/14712598.2017.1366445. PMID: 28832261
Localized bladder cancer.
Izawa JI, Grossman HB
Curr Treat Options Oncol 2000 Dec;1(5):423-32. doi: 10.1007/s11864-000-0070-5. PMID: 12057150

Clinical prediction guides

Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR
Cells 2023 Jun 12;12(12) doi: 10.3390/cells12121611. PMID: 37371081Free PMC Article
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS
Cancer 2022 Mar 15;128(6):1194-1205. Epub 2021 Dec 9 doi: 10.1002/cncr.34057. PMID: 34882781
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J
Clin Cancer Res 2021 Jan 1;27(1):43-51. Epub 2020 Oct 27 doi: 10.1158/1078-0432.CCR-20-2488. PMID: 33109737
Immunotherapy Advances in Urothelial Carcinoma.
Jain RK, Snyders T, Nandagopal L, Garje R, Zakharia Y, Gupta S
Curr Treat Options Oncol 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x. PMID: 30554335
Prospects and progress of immunotherapy for bladder cancer.
Boegemann M, Aydin AM, Bagrodia A, Krabbe LM
Expert Opin Biol Ther 2017 Nov;17(11):1417-1431. Epub 2017 Aug 23 doi: 10.1080/14712598.2017.1366445. PMID: 28832261

Recent systematic reviews

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS
Clin Genitourin Cancer 2020 Oct;18(5):351-360.e3. Epub 2020 Jan 31 doi: 10.1016/j.clgc.2020.01.004. PMID: 32146152Free PMC Article
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC, Sathianathen NJ, Imamura M, Kuntz GM, Risk MC, Dahm P
Cochrane Database Syst Rev 2019 May 14;5(5):CD013336. doi: 10.1002/14651858.CD013336. PMID: 31111956Free PMC Article
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS
Eur Urol 2018 Nov;74(5):597-608. Epub 2018 Jul 13 doi: 10.1016/j.eururo.2018.06.024. PMID: 30017405
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG
BJU Int 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. PMID: 22313502

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...